Trial Profile
A retrospective study evaluating long term efficacy and safety of Secukinumab after abrupt Brodalumab discontinuation in patient with severe psoriasis relapse
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2018
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 05 Apr 2018 New trial record
- 26 Mar 2018 Results published in the Journal of the American Academy of Dermatology